Daptomycin, fosfomycin,or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 4999-5003

  Poeppl, W ^a   Tobudic, S ^a   Lingscheid, T ^a   Plasenzotti, R ^a   Kozakowski, N ^a   Lagler, H ^a   Georgopoulos, A ^a   Burgmann, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; BACTERIUM ISOLATE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; RAT; TIBIA;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DISEASE MODELS, ANIMAL; FOSFOMYCIN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80054685872     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00584-11     Document Type: Article

References (47)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. (Pubitemid 32105280)
2. Aktekin, C. N., A. M. Ozturk, A. Y. Tabak, M. Altay, and F. Korkusuz. 2007. A different perspective for radiological evaluation of experimental osteomyelitis. Skeletal Radiol. 36:945-950. (Pubitemid 47423264)
3. Alos, J. I., P. Garcia-Pena, and J. Tamayo. 2007. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 20:211-215. (Pubitemid 47326190)
4. Andrews, J. M., et al. 1983. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J. Antimicrob. Chemother. 12:357-361. (Pubitemid 14232718)
5. Cai, Y., Y. Fan, R. Wang, M. M. An, and B. B. Liang. 2009. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J. Antimicrob. Chemother. 64:563-566.
6. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Cremieux, A. C., and C. Carbon. 1997. Experimental models of bone and prosthetic joint infections. Clin. Infect. Dis. 25:1295-1302. (Pubitemid 28022661)
8. Cubist Pharmaceuticals. 2003. Cubicin (daptomycin for injection) package insert. Cubist Pharmaceuticals, Lexington, MA.
9. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
10. Debbia, E., A. Pesce, and G. C. Schito. 1988. In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob. Agents Chemother. 32:279-281. (Pubitemid 18061394)
11. Falagas, M. E., K. P. Giannopoulou, G. N. Kokolakis, and P. I. Rafailidis. 2008. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46:1069-1077. (Pubitemid 351589875)
12. Falagas, M. E., K. P. Giannopoulou, F. Ntziora, and P. J. Papagelopoulos. 2007. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 30:202-209. (Pubitemid 47126811)
13. Gould, I. M., and F. M. MacKenzie. 2002. Antibiotic exposure as a risk factor for emergence of resistance: the influence of concentration. Symp. Ser. Soc. Appl. Microbiol. 2002:78S-84S. (Pubitemid 34535509)
14. Horii, T., T. Kimura, K. Sato, K. Shibayama, and M. Ohta. 1999. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob. Agents Chemother. 43:789-793. (Pubitemid 29165741)
15. Joukhadar, C., P. S. S. A. Kugler, C. Wennersten, R. M. Moellering, Jr., and G. Eliopoulos. 2010. Bactericidal effects of fosfomycin against daptomycin resistant strains of Staphylococcus aureus, poster 16. Österreichischer Infektionskongress, Saalfelden, Austria.
16. Lamp, K. C., L. V. Friedrich, L. Mendez-Vigo, and R. Russo. 2007. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am. J. Med. 120:S13-20. (Pubitemid 47464123)
17. Landersdorfer, C. B., J. B. Bulitta, M. Kinzig, U. Holzgrabe, and F. Sorgel. 2009. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin. Pharmacokinet. 48:89-124.
18. Liebowitz, L. D., J. Saunders, L. J. Chalkley, and H. J. Koornhof. 1988. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide. Antimicrob. Agents Chemother. 32:24-26. (Pubitemid 18026490)
19. Luu, Q. N., T. B. Buxton, D. R. Nelson, and J. P. Rissing. 1989. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 8:562-563. (Pubitemid 19158962)
20. Mader, J. T., and K. Adams. 1989. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:689-692. (Pubitemid 19120013)
21. Marchese, A., L. Gualco, E. A. Debbia, G. C. Schito, and A. M. Schito. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22(Suppl. 2):53-59.
22. Meissner, A., R. Haag, and R. Rahmanzadeh. 1989. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 17:146-151. (Pubitemid 19151438)
23. Mikuniya, T., et al. 2007. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J. Infect. Chemother. 13:285-290. (Pubitemid 350059914)
24. Morikawa, K., M. Nonaka, I. Torii, and S. Morikawa. 2003. Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model. Int. J. Antimicrob. Agents 21:334-339. (Pubitemid 36397966)
25. Morikawa, K., M. Nonaka, Y. Yoshikawa, and I. Torii. 2005. Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int. J. Antimicrob. Agents 25:44-50. (Pubitemid 40023345)
26. Nakazawa, H., Y. Kikuchi, T. Honda, T. Isago, and M. Nozaki. 2003. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J. Infect. Chemother. 9:304-309. (Pubitemid 38031325)
27. Olsson-Liljequist, B., and L. G. Burman. 1993. Introducing fosfomycin for surgical prophylaxis - emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand. J. Infect. Dis. 25:725-733. (Pubitemid 24017083)
28. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
29. Patel, M., Y. Rojavin, A. A. Jamali, S. J. Wasielewski, and C. J. Salgado. 2009. Animal models for the study of osteomyelitis. Semin. Plast. Surg. 23:148-154.
30. Poeppl, W., et al. 2010. Comparative efficacies of daptomycin, fosfomycin, and its combination in a rat model of chronic MRSA-osteomyelitis, poster 3943. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
31. Poeppl, W., et al. 2011. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:931-933.
32. Poeppl, W., et al. 2010. Comparative efficacies of daptomycin, fosfomycin, and its combination in a rat model of chronic MRSA-osteomyelitis, poster 19. Abstr. 14th Sci. Meet. Eur. Soc. Chemother./Infect. Dis., Vienna, Austria.
33. Popovic, M., D. Steinort, S. Pillai, and C. Joukhadar. 2009. Fosfomycin: an old, new friend? Eur. J. Clin. Microbiol. Infect. Dis. 29:127-142.
34. Rice, D. A., and L. Mendez-Vigo. 2009. Daptomycin in bone and joint infections: a review of the literature. Arch. Orthop. Trauma Surg. 129:1495-1504.
35. Rice, L. B., C. T. Eliopoulos, J. D. Yao, G. M. Eliopoulos, and R. C. Moellering, Jr. 1992. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn. Microbiol. Infect. Dis. 15:173-176.
36. Rissing, J. P. 1990. Animal models of osteomyelitis. Knowledge, hypothesis, and speculation. Infect. Dis. Clin. North Am. 4:377-390.
37. Rouse, M. S., et al. 2006. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J. Antimicrob. Chemother. 57:301-305. (Pubitemid 43160173)
38. Sader, H. S., and R. N. Jones. 2006. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin. Infect. Dis. 43:798-799, author reply 799-800.
39. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
40. Sakoulas, G., G. M. Eliopoulos, J. Alder, and C. T. Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718. (Pubitemid 36548559)
41. Schintler, M. V., et al. 2009. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J. Antimicrob. Chemother. 64:574-578.
42. Schito, G. C. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22(Suppl. 2):79-83.
43. Takahata, S., et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 35:333-337.
44. Thauvin, C., J. F. Lemeland, G. Humbert, and J. P. Fillastre. 1988. Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 32:919-921.
45. Traunmuller, F., et al. 2010. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. 65:1252-1257.
46. Yin, L. Y., J. H. Calhoun, J. K. Thomas, S. Shapiro, and A. Schmitt-Hoffmann. 2008. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1618-1622. (Pubitemid 351614651)
47. Zak, O., et al. 1982. Experimental staphylococcal osteomyelitis in rats: therapy with rifampin and cloxacillin alone or in combination, p. 973-974. In P. Perti and G. Grassi (ed.), Current chemotherapy and immunotherapy. American Society for Microbiology, Washington, DC.